Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GMP Warning Letter: Teva Preempts FDA In Disclosing Problems At Jerusalem Plant

Executive Summary

Generic giant Teva took the unusual step of disclosing the entire contents of a Jan. 31 FDA warning letter about good manufacturing process failings, as part of a Securities and Exchange Commission filing it posted online two days later.

You may also be interested in...

New Teva CEO’s Initial Priorities Are Manufacturing, Copaxone, R&D

Teva’s new CEO, Jeremy Levin, has been emphasizing manufacturing efficiency, global compliance and a more focused R&D structure in initial comments to Wall Street.

Teva’s U.S. Generic Sales Rebound With Late-Year Launches, Ranbaxy Lipitor Deal

The Israel-based manufacturer saw its full-year U.S. generic revenues drop 32% due to expired marketing exclusivities and manufacturing problems at two plants. However, the fourth quarter brought a rebound, thanks to launches of generic Zyprexa and Combivir and a profit-sharing agreement on atorvastatin.

Did Aurobindo Destroy Its Credibility With FDA Along With A Microbial Plate?

A U.S. FDA warning letter coming on top of an import alert suggests the agency doesn't trust India-based Aurobindo Pharma's quality control

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts